[Seroepidemiologic study of hepatitis A in the community of Madrid during the year 2002].
BACKGROUND
The aim of this study was to investigate the prevalence and risk factors associated with hepatitis A virus (HAV) infection in a representative population sample to determine who can benefit from vaccination strategies and to investigate the age limit at which previous HAV antibody screening is not required.


METHODS
From April to September 2002, we studied a total of 557 patients, 90 children and 467 blood donors, aged 1-65 years. Information on demographic variables (age, gender, place of residence and education level) was recorded. Patients with history of hepatitis or other liver diseases were excluded. Anti-HAV antibodies (IgG) were determined with an automated enzyme immunoassay (AxSYM, Abbott Diagnostics). The chi-square and Mantel-Haenszel tests were used for the statistical analysis.


RESULTS
The overall prevalence of HAV infection was 41.5%. There was a significant increase in prevalence with age (chi-square TL:205, P < .0001), with rates from the youngest to oldest groups of 5.5%, 23.5%, 28.1%, 64.2% and 93.2%, respectively. Apart from age, the only other risk factor independently associated with prevalence was the level of education, with higher prevalence at the lower education levels (OR 5 2.7; chi-square = 32.11, P < .0001).


CONCLUSIONS
The prevalence of anti-HAV antibodies has decreased in recent years in the community of Madrid. Among the population less than 35 years of age, 75% of individuals are susceptible to the infection and could benefit from universal vaccination without previous screening for anti-HAV antibodies.
Junquera
Sonia
S
Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Madrid, Spain. sojuba@hotmail.com
Mateos
Marisa
M
Lasa
Elena
E
Chacón
Jesús
J
Baquero
Fernando
F
D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D002648:Child; D002675:Child, Preschool; D004522:Educational Status; D005260:Female; D006506:Hepatitis A / Q000453:epidemiology*; D035922:Hepatitis A Antibodies / Q000097:blood*; D022362:Hepatitis A Vaccines; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D013030:Spain / Q000453:epidemiology
D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines